MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study.

被引：21

作者：

Janjigian, Yelena Y.

Van Cutsem, Eric

Muro, Kei

Wainberg, Zev A.

Al-Batran, Salah-Eddin

Hyung, Woo Jin

Molena, Daniela

Evans, Brent

Ruscica, Dario

Robbins, Scott H.

Negro, Alejandra

Tabernero, Josep

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Hosp Gasthuisberg, Leuven, Belgium

[3] KU Leuven, Leuven, Belgium

[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA

[6] Univ Canc Ctr, Frankfurt, Germany

[7] Univ Coll Med, Seoul, South Korea

[8] AstraZeneca, Gaithersburg, MD USA

[9] UVic UCC, Vall dHebron Univ Hosp & Vall dHebron Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS4151

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4151

引用

页数：3

共 50 条

[1] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, double-blind, placebo-controlled, phase 3 study
Janjigian, Yelena
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
[2] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, doubleblind, placebo-controlled, phase 3 study
Al-Batran, S. -E
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Hyung, W. J.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S. H.
Negro, A.
Tabernero, J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
[3] MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Al-Batran, S.
Hyung, W.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S.
Negro, A.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S118 - S118
[4] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Marcovitz, Michelle
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
FUTURE ONCOLOGY, 2022, 18 (20) : 2465 - 2473
[5] Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Janjigian, Yelena Y.
Al-Batran, Salah-Eddin
Wainberg, Zen A.
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C. S.
Liberman, Moishe
Oliden, Victor C.
Bilici, Mehmet
Kurland, John
Xynos, Ioannis
Mann, Helan
Tabernero, Josep
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S44 - S45
[6] Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
Park, S.
Sun, J-M
Choi, Y-L
Oh, D.
Kim, H. K.
Lee, T.
Chi, S. A.
Lee, S-H
Choi, Y. S.
Jung, S-H
Ahn, M-J
Ahn, Y. C.
Park, K.
Shim, Y. M.
ESMO OPEN, 2022, 7 (01)
[7] Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shah, Manish A.
Shitara, Kohei
Lordick, Florian
Bang, Yung-Jue
Tebbutt, Niall C.
Metges, Jean-Phillippe
Muro, Kei
Lee, Keun-Wook
Shen, Lin
Tjulandin, Sergei
Hays, John L.
Starling, Naureen
Xu, Rui-Hua
Sturtz, Keren
Fontaine, Marilyn
Oh, Cindy
Brooks, Emily M.
Xu, Bo
Li, Wei
Li, Chiang J.
Borodyansky, Laura
Van Cutsem, Eric
CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3686 - 3694
[8] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
Janjigian, Yelena Yuriy
Bang, Yung-Jue
Fuchs, Charles S.
Qin, Shukui
Satoh, Taroh
Shitara, Kohei
Tabernero, Josep
Van Cutsem, Eric
Cao, Z. Alexander
Chen, Xinqun
Kang, S. Peter
Shih, Chie-Schin
Chung, Hyun Cheol
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Janjigian, Yelena Y.
Al-Batran, Salah-Eddin
Wainberg, Zev A.
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan S.
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C. S.
Liberman, Moishe
Castro Oliden, Victor
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 245 - 246
[10] Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study
Gupta, Pawan Kumar
Maheshwari, Sunil
Cherian, Joe Joseph
Goni, Vijay
Sharma, Arun Kumar
Tripathy, Sujith Kumar
Talari, Keerthi
Pandey, Vivek
Sancheti, Parag Kantilal
Singh, Saurabh
Verma, Nikhil N.
Kumar, Uday
AMERICAN JOURNAL OF SPORTS MEDICINE, 2023, 51 (09): : 2254 - 2266

← 1 2 3 4 5 →